Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Greenovation Biotech GmbH. (3/9/15). "Press Release: Greenovation Successfully Completes Preclinical Toxicology Studies of alpha–Galactosidase". Freiburg.

Organisation Organisation Greenovation Biotech GmbH
Products Product Moss-aGal (recombinant human alpha-galactosidase)
  Product 2 preclinical research
Person Person Frischmuth, Thomas (Panatecs 201205– Managing Director + Greenovation 201105 Managing Director + baseclick)
     


Greenovation Biotech GmbH has successfully completed GLP toxicology studies in non-human primates, and has demonstrated that the moss-aGal (Agalsidase) is safe and very well-tolerated in repeated high dose administrations. The plant-based cGMP manufacturing process resulted in a high yield batch of moss-aGal to be used in upcoming clinical trials.

The GLP toxicology studies in non-human primates demonstrate the moss-aGal to be safe and well tolerated at a dose of 5 to 10 fold higher than the expected human therapeutic dose. In summary, the study investigated intravenous administration of moss-aGal via two 40-minute infusions at doses of either 0 or 5 mg/kg to male and female cynomolgus monkeys. As a result, the study concludes that moss-aGal was very well tolerated under the given study conditions and did not reveal any treatment-related findings. Thus, the no-observed-adverse-effect-level (NOAEL) is considered to be the tested dose level of 5 mg/kg.

“The successful cGMP manufacturing of moss-aGal in the moss expression plattform and the successfully concluded toxicology studies are major developmental milestones for Greenovations alpha-Galactosidase program. Currently we are working on our regulatory package for a Phase I/II clinical trial which includes Fabry Disease patients,“ stated Dr. Thomas Frischmuth, CEO of Greenovation. “Achieving a proprietary, commercially viable manufacturing process of alpha-Galactosidase demonstrates the successful development of Greenovation into a biopharmaceutical company.”


About Greenovation Biotech GmbH

Greenovation develops next generation biopharmaceuticals in particular in rare disease indications. Human alpha-Galactosidase is the company’s lead product being developed as enzyme-replacement therapy (ERT) for Fabry Disease. Results of the recently completed pre-clinical program clearly indicate superiority features with respect to pharmacokinetics (delayed clearance), pharmacodynamics and biodistribution. A multi-center clinical Phase I/II study with this candidate will be undertaken in Europe.

Greenovation’s development pipeline further includes glucocerebrosidase (glucerase, for ERT of Gaucher’s disease), complement factor H (to treat atypical HUS), antibody (IgG) programs for enhanced ADCC as well as growth factors (FGF7/KGF, EGF, HGF) for various applications.


Contact and further information

Greenovation Biotech GmbH
Manon Bartusel
Tel. +49 (0)761 470 99 0
mbartusel@greenovation.com
www.greenovation.com

   
Record changed: 2017-04-02

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Greenovation Biotech GmbH


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px